INDIVIOR PHARMACEUTICALS, INC. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+19.7% +$59M
$358M
Cost of Revenue↑+39.6% +$19M
$67M
Gross Profit↑+16.8% +$42M
$292M
R&D↓-32.3% -$10M
$21M
SG&A↑+8.0% +$14M
$189M
D&A↓-60.0% -$3M
$2M
Operating Income↑+76.1% +$35M
$81M
EBITDA↑+62.7% +$32M
$83M
Interest Expense↑+20.0% +$2M
$12M
Interest Income↑+20.0% +$1M
$6M
Other Income/Expense↑+300.0% +$9M
$6M
Pretax Income↑+113.2% +$43M
$81M
Tax Provision↓-162.5% -$13M
$-5M
Net Income↑+385.7% +$81M
$102M
Gross Margin↓-2.0pts
81.6%
Operating Margin↑+7.2pts
22.6%
Net Margin↑+21.5pts
28.5%
Effective Tax Rate↓-40.2pts
-13.5%
Deferred Tax Assets
$38M
ETR (Continuing Operations)↓-52.8pts
12.2%
ETR Federal Statutory↑+0.0pts
25.0%
ETR State + Local (pp)
0.0%
ETR Foreign Differential (pp)
8.8%
Revenue YoY Variation
19.7%
Income YoY Variation
76.1%
Revenue QoQ Variation↑+16.6pts
14.0%
Income QoQ Variation↑+56.9pts
88.4%